Literature DB >> 23549648

Neuromuscular and systemic presentations in adults: diagnoses beyond MERRF and MELAS.

Bruce H Cohen1.   

Abstract

Mitochondrial diseases are a diverse group of inherited and acquired disorders that result in inadequate energy production. They can be caused by inheritable genetic mutations, acquired somatic mutations, and exposure to toxins (including some prescription medications). Normal mitochondrial physiology is responsible, in part, for the aging process itself, as free radical production within the mitochondria results in a lifetime burden of oxidative damage to DNA, especially the mitochondrial DNA that, in turn, replicate the mutational burden in future copies of itself, and lipid membranes. Primary mitochondrial diseases are those caused by mutations in genes that encode for mitochondrial structural and enzymatic proteins, and those proteins required for mitochondrial assembly and maintenance. A number of common adult maladies are associated with defective mitochondrial energy production and function, including diabetes, obesity, hyperthyroidism, hypothyroidism, and hyperlipidemia. Mitochondrial dysfunction has been demonstrated in many neurodegenerative disorders, including Alzheimer's disease, Parkinson disease, amyotrophic lateral sclerosis, and some cancers. Polymorphisms in mitochondrial DNA have been linked to disease susceptibility, including death from sepsis and survival after head injury. There is considerable overlap in symptoms caused by primary mitochondrial diseases and those illnesses that affect mitochondrial function, but are not caused by primary mutations, as well as disorders that mimic mitochondrial diseases, but are caused by other identified mutations. Evaluation of these disorders is complex, expensive, and not without false-negative and false-positive results that can mislead the physician. Most of the common heritable mitochondrial disorders have been well-described in the literature, but can be overlooked by many clinicians if they are uneducated about these disorders. In general, the evaluation of the classic mitochondrial disorders has become straightforward if the clinician recognized the phenotype and orders appropriate confirmatory testing. However, the majority of patients referred for a mitochondrial evaluation do not have a clear presentation that allows for rapid identification and testing. This article provides introductory comments on mitochondrial structure, physiology, and genetics, but will focus on the presentation and evaluation of adults with mitochondrial symptoms, but who may not have a primary mitochondrial disease.

Entities:  

Mesh:

Year:  2013        PMID: 23549648      PMCID: PMC3625384          DOI: 10.1007/s13311-013-0188-3

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  76 in total

Review 1.  Protective effects and mechanisms of sirtuins in the nervous system.

Authors:  Feng Zhang; Suping Wang; Li Gan; Peter S Vosler; Yanqin Gao; Michael J Zigmond; Jun Chen
Journal:  Prog Neurobiol       Date:  2011-09-10       Impact factor: 11.685

Review 2.  Liver mitochondria and insulin resistance.

Authors:  Guillaume Vial; Hervé Dubouchaud; Xavier M Leverve
Journal:  Acta Biochim Pol       Date:  2010-11-16       Impact factor: 2.149

3.  Mitochondrial enzymes discriminate between mitochondrial disorders and chronic fatigue syndrome.

Authors:  Bart Smits; Lambert van den Heuvel; Hans Knoop; Benno Küsters; Antoon Janssen; George Borm; Gijs Bleijenberg; Richard Rodenburg; Baziel van Engelen
Journal:  Mitochondrion       Date:  2011-06-02       Impact factor: 4.160

Review 4.  Mitochondrial syndromes with leukoencephalopathies.

Authors:  Lee-Jun C Wong
Journal:  Semin Neurol       Date:  2012-03-15       Impact factor: 3.420

Review 5.  Mitochondrial disorders and the eye.

Authors:  Samantha A Schrier; Marni J Falk
Journal:  Curr Opin Ophthalmol       Date:  2011-09       Impact factor: 3.761

Review 6.  The use of neuroimaging in the diagnosis of mitochondrial disease.

Authors:  Seth D Friedman; Dennis W W Shaw; Gisele Ishak; Andrea L Gropman; Russell P Saneto
Journal:  Dev Disabil Res Rev       Date:  2010

Review 7.  Mitochondrial dysfunction in nonalcoholic steatohepatitis.

Authors:  Gaetano Serviddio; Francesco Bellanti; Gianluigi Vendemiale; Emanuele Altomare
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2011-04       Impact factor: 3.869

8.  Maternally inherited diabetes and deafness is a distinct subtype of diabetes and associates with a single point mutation in the mitochondrial tRNA(Leu(UUR)) gene.

Authors:  J M van den Ouweland; H H Lemkes; R C Trembath; R Ross; G Velho; D Cohen; P Froguel; J A Maassen
Journal:  Diabetes       Date:  1994-06       Impact factor: 9.461

9.  Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity.

Authors:  Joanna D Stewart; Rita Horvath; Enrico Baruffini; Iliana Ferrero; Stefanie Bulst; Paul B Watkins; Robert J Fontana; Christopher P Day; Patrick F Chinnery
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

Review 10.  Disorders of the optic nerve in mitochondrial cytopathies: new ideas on pathogenesis and therapeutic targets.

Authors:  Kamil S Sitarz; Patrick F Chinnery; Patrick Yu-Wai-Man
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

View more
  8 in total

1.  Mitochondrial Disorders May Mimic Amyotrophic Lateral Sclerosis at Onset.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  Sultan Qaboos Univ Med J       Date:  2016-02-02

Review 2.  Modification of the wobble uridine in bacterial and mitochondrial tRNAs reading NNA/NNG triplets of 2-codon boxes.

Authors:  M Eugenia Armengod; Salvador Meseguer; Magda Villarroya; Silvia Prado; Ismaïl Moukadiri; Rafael Ruiz-Partida; M José Garzón; Carmen Navarro-González; Ana Martínez-Zamora
Journal:  RNA Biol       Date:  2014       Impact factor: 4.652

Review 3.  Myositis Mimics.

Authors:  E Harlan Michelle; Andrew L Mammen
Journal:  Curr Rheumatol Rep       Date:  2015-10       Impact factor: 4.592

4.  Single- and multiple-dose safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ASP0367, or bocidelpar sulfate, a novel modulator of peroxisome proliferator-activated receptor delta in healthy adults: Results from a phase 1 study.

Authors:  Mototsugu Ito; Sitra Tauscher-Wisniewski; Ronald A Smulders; Tomasz Wojtkowski; Akihiro Yamada; Akira Koibuchi; Tolga Uz; Gerard J Marek; Ronald D Goldwater
Journal:  Muscle Nerve       Date:  2021-10-28       Impact factor: 3.852

5.  Mitochondrial Myopathy in Follow-up of a Patient With Chronic Fatigue Syndrome.

Authors:  Fernando Galán; Isabel de Lavera; David Cotán; José A Sánchez-Alcázar
Journal:  J Investig Med High Impact Case Rep       Date:  2015-09-24

Review 6.  Mitochondrial Donation: A Boon or Curse for the Treatment of Incurable Mitochondrial Diseases.

Authors:  Nishtha Saxena; Nancy Taneja; Prakriti Shome; Shalini Mani
Journal:  J Hum Reprod Sci       Date:  2018 Jan-Mar

7.  A Novel Mutation of Mitochondrial T14709C Causes Myoclonic Epilepsy with Ragged Red Fibers Syndrome in a Chinese Patient.

Authors:  Rui Ban; Jun-Hong Guo; Chuan-Qiang Pu; Qiang Shi; Hua-Xu Liu; Yu-Tong Zhang
Journal:  Chin Med J (Engl)       Date:  2018-07-05       Impact factor: 2.628

8.  A Mitochondrial Disorder in a Middle Age Iranian Patient: Report of a Rare Case.

Authors:  Mostafa Almasi; Mohammad Reza Motamed; Masoud Mehrpour; Bahram Haghi-Ashtiani; Fahimeh Haji Akhondi; Yalda Nilipour; Seyed-Mohammad Fereshtehnejad
Journal:  Basic Clin Neurosci       Date:  2017 Jul-Aug
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.